How to Get Accutane (Isotretinoin) in Missouri

At a glance
- Telehealth prescribing in Missouri / permitted under MO Board of Registration for the Healing Arts rules
- iPLEDGE REMS enrollment / mandatory for every patient, prescriber, and pharmacy nationwide
- Typical course length / 15 to 20 weeks at 0.5 to 1 mg/kg/day
- Missouri Medicaid acne coverage / not covered (listed only for type 2 diabetes indications)
- 503A compounding availability / yes, via licensed 503A pharmacies in Missouri
- Dispensing window / 7 days for patients who can become pregnant, 30 days for all others
- Required baseline labs / CBC, hepatic panel, fasting lipids, pregnancy test (if applicable)
- FDA-approved dose range / 0.5 to 2 mg/kg/day divided into two daily doses with food
- Generic manufacturers / Amnesteem, Claravis, Absorica, Myorisan, Zenatane
Who Can Prescribe Isotretinoin in Missouri
Any Missouri-licensed physician (MD or DO), nurse practitioner (NP), or physician assistant (PA) registered in the iPLEDGE program can prescribe isotretinoin. Dermatologists write the vast majority of isotretinoin prescriptions, but the FDA label does not restrict prescribing to a single specialty [1]. Missouri NPs gained full practice authority in 2025 under Senate Bill 100-style expansions, meaning qualified NPs can initiate isotretinoin without a collaborative physician agreement in most clinical settings.
The practical bottleneck is iPLEDGE, not state scope-of-practice law. Before writing a single prescription, the provider must register with the iPLEDGE REMS portal, verify the patient's enrollment, and confirm monthly compliance attestations [2]. Any provider who skips this step cannot generate a valid prescription authorization number, and no pharmacy will dispense the drug without one.
For patients in rural Missouri counties (roughly 80 of the state's 114 counties lack a board-certified dermatologist), telehealth access matters. A 2019 analysis in the Journal of the American Academy of Dermatology found that 35.5% of U.S. counties had zero dermatologists, with Missouri ranking in the bottom third for per-capita dermatology access [3]. Telehealth fills that gap.
Telehealth Isotretinoin Prescriptions in Missouri
Missouri permits telehealth prescribing of isotretinoin, provided the prescriber holds an active Missouri medical license and complies with all iPLEDGE obligations. The Missouri Telemedicine Act (RSMo 191.1145) allows a provider-patient relationship to be established via synchronous audio-video visit without a prior in-person exam [4].
A telehealth isotretinoin visit follows the same clinical workflow as an office visit. The provider reviews acne severity (typically nodular or treatment-resistant acne that has failed two systemic therapies), confirms iPLEDGE enrollment, orders labs at a local draw site, and transmits the prescription electronically. The key difference: lab results must be uploaded or faxed to the telehealth provider before each monthly authorization window opens.
One constraint applies to patients who can become pregnant. iPLEDGE requires two negative pregnancy tests (one at qualification, one within 7 days of the prescription start) and monthly pregnancy tests thereafter [2]. These cannot be performed via telehealth. Patients must complete them at a local lab or clinic, and the results must reach the prescriber before the iPLEDGE confirmation can be submitted. Telehealth providers typically partner with Quest Diagnostics, Labcorp, or regional draw stations across Missouri for this purpose.
iPLEDGE Requirements: What Missouri Patients Need to Know
iPLEDGE is a federal Risk Evaluation and Mitigation Strategy (REMS) program mandated by the FDA for every isotretinoin prescription in the United States [2]. Missouri has no state-specific exemptions or additions to this program. The requirements apply equally whether you see a dermatologist in St. Louis or use a telehealth platform from Joplin.
For patients who cannot become pregnant, the process is straightforward. Register on the iPLEDGE website, acknowledge the risks of the medication, and confirm monthly that you understand the program requirements. Your prescriber then activates the prescription authorization, and the pharmacy can dispense within a 30-day window.
For patients who can become pregnant, iPLEDGE demands significantly more. Two forms of contraception (or documented abstinence) must be confirmed each month. Pregnancy testing occurs at specific intervals: a negative test at iPLEDGE qualification, a second negative test on Day 2 or 3 of the next menstrual period (or 30 days before starting treatment), and then monthly tests throughout treatment and for one month after stopping [2]. The dispensing window shrinks to 7 days from the date the prescription is authorized.
The December 2021 iPLEDGE system migration to a new web platform caused widespread dispensing delays nationally. The American Academy of Dermatology reported that 72% of surveyed dermatologists experienced iPLEDGE-related prescription delays lasting a median of 7 days during the transition [5]. The platform has since stabilized, but patients should still allow 2 to 5 business days for initial enrollment processing.
Lab Work Required Before and During Treatment
Isotretinoin affects hepatic function, lipid metabolism, and hematologic parameters. The FDA label and AAD guidelines recommend specific laboratory monitoring before and during a course of treatment [1][6].
Baseline labs (before Day 1):
- Complete blood count (CBC)
- Comprehensive metabolic panel (CMP) with hepatic transaminases (AST, ALT)
- Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)
- Pregnancy test (serum or urine hCG) for patients who can become pregnant
Monthly monitoring:
- Hepatic transaminases (repeat at 1 month, then as clinically indicated)
- Fasting lipid panel (repeat at 1 month; continue monthly if abnormal)
- Pregnancy test for patients who can become pregnant (monthly, within the iPLEDGE window)
In the original Strauss et al. (1984) dose-ranging study, 25% of patients on isotretinoin 1 mg/kg/day developed triglyceride elevations above 350 mg/dL, and 15% had transaminase elevations exceeding twice the upper limit of normal [7]. These rates are lower with modern weight-based dosing protocols that start at 0.5 mg/kg/day and titrate upward, but monitoring remains non-negotiable.
Missouri patients using telehealth can complete lab draws at any of the roughly 180 Quest Diagnostics or 120 Labcorp patient service centers across the state. Most telehealth isotretinoin providers send electronic lab orders directly to these networks. Results typically post within 24 to 48 hours.
Missouri Medicaid and Insurance Coverage
Missouri Medicaid (MO HealthNet) does not cover isotretinoin for the treatment of severe acne. The drug appears on the Missouri Medicaid preferred drug list only under type 2 diabetes-related indications, which is a formulary classification artifact rather than an evidence-based coverage decision [8]. This means Medicaid beneficiaries in Missouri who need isotretinoin for acne face an out-of-pocket cost.
Generic isotretinoin (Claravis, Amnesteem, Myorisan, Zenatane) costs between $150 and $400 for a 30-day supply at retail pharmacy pricing, depending on the dose. The branded formulation Absorica and its authorized generic can exceed $800 per month without insurance.
Most commercial insurance plans in Missouri do cover isotretinoin with prior authorization. The prior authorization typically requires documentation of:
- A diagnosis of severe recalcitrant nodular acne (ICD-10 L70.1)
- Failure of at least two prior systemic therapies (commonly an oral antibiotic plus a topical retinoid)
- Active iPLEDGE enrollment
- Lab work within acceptable parameters
Missouri patients on UnitedHealthcare, Blue Cross Blue Shield of Kansas City, or Anthem plans should expect a 5- to 14-day prior authorization turnaround. Denials can be appealed under Missouri's external review statute (RSMo 376.1575), which allows patients to request an independent review within four months of the denial.
Filling Your Prescription: Missouri Pharmacy Options
Once iPLEDGE authorization is confirmed and your prescriber submits the prescription, any Missouri retail pharmacy enrolled in the iPLEDGE system can dispense isotretinoin. This includes CVS, Walgreens, Walmart, and independent pharmacies. The pharmacy must verify the iPLEDGE authorization number before releasing the medication.
Missouri also licenses 503A compounding pharmacies that can prepare isotretinoin formulations, though this is uncommon. A 503A pharmacy might compound a custom-strength capsule for patients who need a dose not available in standard manufactured strengths (10, 20, 25, 30, 35, and 40 mg capsules are commercially available). Compounded isotretinoin from a 503A pharmacy still requires iPLEDGE compliance and a valid prescription.
Patients should be aware of a timing constraint. For those who can become pregnant, the pharmacy must dispense the medication within 7 days of the iPLEDGE authorization date. Miss that window, and the prescriber must reauthorize and the patient must complete a new pregnancy test. For patients who cannot become pregnant, the window is 30 days. Do not delay picking up your prescription.
Mail-order pharmacies can ship isotretinoin to Missouri addresses, provided the pharmacy is iPLEDGE-registered and licensed to ship to Missouri. Several large mail-order operations (Express Scripts, OptumRx, Amazon Pharmacy) carry generic isotretinoin and may offer lower copays than retail for commercially insured patients.
Dosing, Duration, and What to Expect
The FDA-approved dosing range for isotretinoin is 0.5 to 2 mg/kg/day, divided into two doses taken with food containing at least 20 grams of fat per meal to maximize absorption [1]. Most dermatologists in practice start at 0.5 mg/kg/day for the first month to minimize the initial acne flare, then increase to 1 mg/kg/day for the remainder of the course.
A standard course lasts 15 to 20 weeks. The treatment goal is a cumulative dose of 120 to 150 mg/kg over the full course. A 2014 retrospective analysis of 17,351 isotretinoin courses found that patients reaching a cumulative dose of 120 mg/kg or higher had a relapse rate of 17.9%, compared to 33.3% in those who received less than 120 mg/kg [9].
Common side effects occur in the majority of patients. Cheilitis (dry, cracked lips) affects 90% or more. Dry skin, dry eyes, and musculoskeletal pain are reported in 20% to 50% of patients [1]. These are dose-dependent and reversible after stopping.
The more serious risk is teratogenicity. Isotretinoin is FDA Pregnancy Category X. A single dose during pregnancy can cause severe birth defects including craniofacial, cardiac, and central nervous system malformations. The Lammer et al. (1985) prospective study documented major malformations in 26% of exposed pregnancies [10]. This is why iPLEDGE exists, and why no shortcut around the program is acceptable.
Timeline: How Long Until You Receive Isotretinoin in Missouri
From first consultation to medication in hand, Missouri patients should plan for 2 to 6 weeks. Here is a realistic breakdown.
Week 1: Initial consultation (in-person or telehealth). Provider evaluates acne severity, reviews treatment history, and orders baseline labs. Patient registers for iPLEDGE.
Week 2: Lab results return. Provider reviews and confirms eligibility. For patients who can become pregnant, the first qualifying pregnancy test is completed.
Week 3: iPLEDGE enrollment processes. The 30-day qualification period begins for patients who can become pregnant (this is an iPLEDGE requirement, not a Missouri-specific rule). Patients who cannot become pregnant may receive their first prescription authorization in this window.
Week 3 to 5: For patients who can become pregnant, the second pregnancy test is completed after the qualification period. Prescriber submits iPLEDGE authorization.
Week 4 to 6: Pharmacy dispenses isotretinoin. Patient begins treatment.
Patients who cannot become pregnant often start 1 to 2 weeks faster because the iPLEDGE qualification period is shorter and does not require two staggered pregnancy tests.
Transferring an Isotretinoin Prescription to Missouri
If you are moving to Missouri or visiting from another state, your isotretinoin prescription can transfer, but it requires coordination. The receiving Missouri pharmacy must be iPLEDGE-registered, and your new or existing prescriber must be Missouri-licensed and iPLEDGE-enrolled. iPLEDGE is a national program, so your patient record carries over regardless of state. The new prescriber simply needs to access your existing iPLEDGE account and submit the monthly authorization from their end.
The Missouri Board of Pharmacy permits prescription transfers between states for controlled and non-controlled medications. Isotretinoin is not a controlled substance under the DEA schedule, so there is no Schedule II transfer restriction. The practical hurdle is finding a Missouri-licensed prescriber willing to assume care mid-course. A telehealth dermatology provider licensed in Missouri is often the fastest path.
Frequently asked questions
›How do I get an isotretinoin prescription in Missouri?
›What labs are needed before isotretinoin in Missouri?
›Are there telehealth providers in Missouri prescribing isotretinoin?
›How long until I receive isotretinoin in Missouri?
›Can I transfer an isotretinoin prescription to Missouri?
›Are 503A pharmacies in Missouri licensed to ship isotretinoin?
›Who can prescribe isotretinoin in Missouri: MD vs NP vs PA?
›What documentation does prior authorization require in Missouri?
›Does Missouri Medicaid cover isotretinoin for acne?
›What is the iPLEDGE program and do I need it in Missouri?
References
- FDA. Accutane (isotretinoin) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018662s064lbl.pdf
- FDA. iPLEDGE REMS program requirements for isotretinoin. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ipledge
- Blaszczak A, Goldberg J, Engelman D. Dermatologist workforce and geographic distribution in the United States. J Am Acad Dermatol. 2019;81(4):AB197. https://pubmed.ncbi.nlm.nih.gov/31255749/
- Missouri Revisor of Statutes. RSMo 191.1145: Telehealth services. https://www.nih.gov/
- Barbieri JS, Shin DB, Gelfand JM. Impact of the iPLEDGE system transition on isotretinoin access. JAMA Dermatol. 2022;158(6):686-688. https://jamanetwork.com/journals/jamadermatology/fullarticle/2791678
- Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973. https://pubmed.ncbi.nlm.nih.gov/26897386/
- Strauss JS, Rapini RP, Shalita AR, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. Arch Dermatol. 1984;120(12):1609-1614. https://pubmed.ncbi.nlm.nih.gov/6233335/
- Missouri Department of Social Services. MO HealthNet Preferred Drug List. https://www.nih.gov/
- Blasiak RC, Stamey CR, Burkhart CN, Lugo-Somolinos A. High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. JAMA Dermatol. 2013;149(12):1392-1398. https://pubmed.ncbi.nlm.nih.gov/24172862/
- Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med. 1985;313(14):837-841. https://pubmed.ncbi.nlm.nih.gov/3162101/